

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of : Confirmation No. 9675  
Mamoru OHASHI et al. : Docket No. 2000\_0486A  
Serial No. 09/529,715 : Group Art Unit 1616  
Filed April 19, 2000 : Examiner S. Gollamudi

FAST-DISSOLVING PHARMACEUTICAL COMPOSITION

RESPONSE UNDER 37. CFR 1.111  
EXPEDITED PROCEDURE  
EXAMINING GROUP 1616

AMENDMENT AFTER FINAL

Assistant Commissioner for Patents,  
Washington, D.C.

Sir:

Responsive to the Official Action dated March 26, 2002, please amend the above-identified application as follows:

IN THE CLAIMS

Please amend the claims as follows:

1. <sup>Thrice</sup> ~~Twice~~ Amended) A fast-dissolving pharmaceutical composition comprising <sup>in a solid dosage form,</sup> micronized (R)-2-(4-bromo-2-fluorobenzyl)-1,2,3,4-tetrahydropyrrolo[1,2-a]pyrazine-4-spiro-3'-pyrrolidine-1,2',3,5'-tetrone (hereinafter referred to as "AS-3201") having a mean particle size of less than about 20  $\mu$ m in a ratio of about 0.5% by weight to about 25% by weight of the total weight of the pharmaceutical composition,

wherein when a dissolution percentage of AS-3201 from the composition is measured according to the Paddle method, 50% or more of the AS-3201 in the composition is dissolved within 15 minutes from the start of the method.